|
2025 Journal Article Harnessing notch signaling to enhance the generation and functionality of human conventional type I dendritic cells for cancer immunotherapy applicationsBalan, Sreekumar, O'Brien, Liam, Peros, Ante, Wang, Xuedi, Leal-Rojas, Ingrid, Mcclain, Christopher, Radford, Kristen J. and Bhardwaj, Nina (2025). Harnessing notch signaling to enhance the generation and functionality of human conventional type I dendritic cells for cancer immunotherapy applications. Cancer Immunology Research, 13 (9), 1328-1341. doi: 10.1158/2326-6066.cir-25-0034 |
|
2025 Journal Article Human cDC1 enhance cytotoxic function of CD226+ terminally exhausted tumor-infiltrating lymphocytesO’Brien, Liam, Buckle, Irina, Leal-Rojas, Ingrid M., Rosendahl, Nikita and Radford, Kristen J. (2025). Human cDC1 enhance cytotoxic function of CD226+ terminally exhausted tumor-infiltrating lymphocytes. OncoImmunology, 14 (1) 2521391, 2521391. doi: 10.1080/2162402x.2025.2521391 |
|
2024 Journal Article Characterization of human engraftment and hemophagocytic lymphohistiocytosis in NSG-SGM3 neonate mice engrafted with purified CD34+ hematopoietic stem cellsLiam, O'Brien, Carina, Walpole, Leal-Rojas, Ingrid M., Svetlana, Shatunova, Andrew, Moore, Winkler, Ingrid G, Camille, Guillerey and Radford, Kristen J. (2024). Characterization of human engraftment and hemophagocytic lymphohistiocytosis in NSG-SGM3 neonate mice engrafted with purified CD34+ hematopoietic stem cells. Experimental Hematology, 130 104134, 104134. doi: 10.1016/j.exphem.2023.11.008 |
|
2022 Other Outputs Establishing humanized mouse models to evaluate immunotherapyO'Brien, Liam (2022). Establishing humanized mouse models to evaluate immunotherapy. PhD Thesis, Mater Research Institute-UQ, The University of Queensland. doi: 10.14264/d2273fa |
|
2021 Journal Article Human CD141+ dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse modelLee, Yoke Seng, O'Brien, Liam J., Walpole, Carina M., Pearson, Frances E., Leal-Rojas, Ingrid M., Masterman, Kelly-Anne, Atkinson, Victoria, Barbour, Andrew and Radford, Kristen J. (2021). Human CD141+ dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse model. Journal for ImmunoTherapy of Cancer, 9 (3) e001963, 1-12. doi: 10.1136/jitc-2020-001963 |
|
2020 Journal Article Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141+ dendritic cells to activate naïve and memory NY-ESO-1-specific CD8+ T cellsMasterman, Kelly-Anne, Haigh, Oscar L., Tullett, Kirsteen M., Leal-Rojas, Ingrid M., Walpole, Carina, Pearson, Frances E., Cebon, Jonathon, Schmidt, Christopher, O'Brien, Liam, Rosendahl, Nikita, Daraj, Ghazal, Caminschi, Irina, Gschweng, Eric H., Hollis, Roger P., Kohn, Donald B., Lahoud, Mireille H. and Radford, Kristen J. (2020). Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141+ dendritic cells to activate naïve and memory NY-ESO-1-specific CD8+ T cells. Journal for ImmunoTherapy of Cancer, 8 (2) e000691, 1-11. doi: 10.1136/jitc-2020-000691 |
|
2020 Conference Publication Human CD141+dendritic cells (cDC1) are impaired in advanced melanoma patients but can be targeted to increase efficacy of anti-PD-1 checkpoint inhibitor therapyO'Brien, Liam, Lee, Yoke Seng, Walpole, Carina, Rojas, Ingrid Leal, Masterman, Kelly-Anne, Atkinson, Victoria, Barbour, Andrew and Radford, Kristen (2020). Human CD141+dendritic cells (cDC1) are impaired in advanced melanoma patients but can be targeted to increase efficacy of anti-PD-1 checkpoint inhibitor therapy. AACR Special Conference on Tumor Immunology and Immunotherapy, Boston, MA, United States, 17-20 November, 2019. Philadelphia, PA, United States: American Association for Cancer Research. |
|
2019 Journal Article Can Dendritic Cell vaccination prevent leukemia relapse?O’Brien, Liam J., Guillerey, Camille and Radford, Kristen J. (2019). Can Dendritic Cell vaccination prevent leukemia relapse?. Cancers, 11 (6) 875, 875. doi: 10.3390/cancers11060875 |
